Share
35,790 Posts.
lightbulb Created with Sketch. 555
clock Created with Sketch. 04/02/20
11:44
Share
Originally posted by hottod
↑
Of course more focus/information flow is going to happen around the lead candidate drug but I don’t agree with the comment that “they seemed to narrow focus down to just that 1 potential drug”.We have previously advised that we are building our delivery platform in the context of AntiSense Oligonucleotide (ASO) drug cargoes…. Our choice of drug cargo has been complemented by a decision on our initial target tissue of interest. We are seeking to deliver these ASO cargoes into the back of the eye to address diseases occurring in the retina. The treatment of inherited retinal diseases is the priority setting for the clinical development of our platform. Our CPP enables the ASO to achieve its effect in the nucleus of cells….We can leverage these results to treat any retinal disease of interest Objective - We are developing multiple drugs for the treatment of blinding eye diseases and are taking them through clinical development Previously PYC has been advancing its cell penetrating peptide technology as a platform to deliver drugs. Now it will be combining that technology with drugs to internally develop a new class of therapies to cure blinding diseases of the eye. Sue Fletcher “We look forward to the clinical development of therapeutics for Retinitis Pigmentosa and other degenerative retinal diseases ” (01/10/19)Not only has our delivery technology improved and matured to the quality required for human therapeutics but we have also recruited and developed the capability to design RNA therapeutics ‘in-house’. PYC’s lead program is the ‘tip of the iceberg’ in the development pipeline and PYC’s second and third drug programs benefit from great efficiencies in the design and testing of the delivery technology already completed. The relatively short amount of time required to design a new RNA therapeutic once the target opportunity has been identified is a major advantage of this class of drugs.
Expand
Sure .... it’s still about getting the first “drug” out of the lab - and finalllllly trying something first in human .... will be the tell all ... until then ?
Last edited by
Akki :
04/02/20
(20min delay)